Looking very certain to go down with overbought levels growingSentiment has slowed, but the buying has continued, maybe to average down. TA-wise, the precedent is clear: by retracing, then stabilizing, consolidating, and continuing.
HUM trade ideas
HUM Bullish Re-Entry – Support Holding with Increased VolumeI re-entered NYSE:HUM on Friday after my stop was triggered earlier. The strong support level is holding well, rejecting lower prices, and volume has increased, confirming renewed buying pressure. The stock remains in a historical uptrend, and with the all-time high (ATH) not far off, the setup offers a solid 1:26 risk-to-reward ratio if momentum continues.
Watching for the next move! 🚀📈
Humana and the health insurance companiesThe business could improve in the next weeks. We understood the change in Politics in USA.
HUM Bullish Setup - 1/20 Risk/Reward Opportunity on 3W Chart!NYSE:HUM is looking strong on the 3-week chart , presenting a bullish setup with a solid upward trendline and price sitting at a strong support level. The chart has recently shown two bullish spike candles, indicating increased buying pressure. The stock is trending toward its all-time high (ATH), which isn't far off, offering a promising upside.
With a 1:20 risk-to-reward ratio until the ATH, this setup is highly favorable if the current support holds. 🚀
215 likely candidate death cross MA oscillators downfallIt has not been confirmed, but downside momentum continues, which might have a lot to do with the sentiment of healthcare. Is there room for improvement and an overhaul of how things are currently run as the administration closes in on taking office? Technically speaking, it has room to run, solid support again at the initial area confirmed by many oscillators, and then no sign of any reversal sentiment or buying pressure to overthrow the bear's sentiment of continuing correction. I am not convinced of a position for a higher move until the correction is complete.
HUM (Daily) downsideHUM has some mild bullish divergence on the daily MACD that caused a nice bounce off strong historical support, but the impulse up is slow and looking more corrective. Maybe it will touch the daily trendline, but it seems to me that a retest of the support is on its way, especially given EPS has been in decline since 2020, and forecasts are not looking positive.
Humana(Extended Hours) | Chart & Forecast SummaryKey Indicators On Trade Set Up In General
1. Push Set Up
2. Range Set up
3. Break & Retest Set Up
Notes On Session
# Humana(Extended Hours)
- Double Formation
* A+ Set Up | Downtrend Area At 410.00 USD
* Resistance | Retracement Area | Subdivision 1
- Triple Formation
* Pennant Structure | Break Out At 270.00 USD
* Neckline | (1) Retracement Area | Subdivision 2
* Trend, Behaviour & Entry | Subdivision 3
Active Sessions On Relevant Range & Elemented Probabilities;
London(Upwards) - NYC(Downwards)
Conclusion | Trade Plan Execution & Risk Management On Demand;
Overall Consensus | Neutral
Humana | HUM | Long at $220.00Humana NYSE:HUM took a nosedive to "crash" levels (based on my selected simple moving averages (SMA)) this morning after a lower-performance rating for a widely used Medicare insurance plan is expected to hurt enrollments for 2025 (and will potentially hit the health insurer's revenue and bonus payments in 2026). However, I view this massive drop as an opportunity for an initial long entry for a great value stock. The company is strong, highly rated among patients, and solid fundamentals despite the anticipated earnings drop. From a technical analysis perspective, it touched my "crash" SMA, but may dip further after a dead cat bounce to the $190s in the coming days or weeks. But, predicting true bottom is a fool's game, so at $220.00, NYSE:HUM is in a personal buy zone for an initial long entry.
Target #1 = $250.00
Target #2 = $275.00
Target #3 = $314.00
Target #4 = $340.00
Reported earlier FLAG breakout now another gap upBased on beautiful earnings, as the estimate and what was reported, the outlook is now favoring, but the price action continues. We are seeing some levels overbought to the rims and need to cool down, releasing the heat of an already hot stock in the TA world, where the precedent is another test at 300. A correction at that time, unless it breaks toward mid-350, as it seems to have stabilized nicely since its infamous gap down, is unlikely.
279 TARGET HAS NOT CHANGED VERY BULLISHOnce in a lifetime, the indicators are not even halfway up to the signal. Even if it meets the center line, that's a staggering 20%. On top of that, the crossover on MACD and curving moving averages are ready to confirm a new bullish trend.
$HUM harmonic update. NYSE:HUM
My spring/summer alert led to a -35% price drop towards our pattern completion for the crab harmonic.
We have now bounced off the PRZ , and I'm targeting the 0.382 fib retracement @ 334.49 .
Key resistance levels are:
249.47 (0.114 fib)
288.18 (0.236 fib)
334.49 (0.382 fib)
>334.49 we can then target the upper trendline (red), and the neckline resistance 409.36 for this possible "Shark" harmonic setup...
HUM Long 11/10/24Asset Class: Stocks
Income Type: Weekly
Symbol: HUM
Trade Type: Long
Trends:
Short Term: Up
Long Term: Down
Set-Up Parameters:
Entry: 251.55
Stop: 227.76
TP1 321.05 (3:1)
Trade idea:
Daily DZ DBR at breakout, with a FVG above it at 1:1 RRR. Possible trend reversal at the daily DZ
!!Be aware of pending Economic Reports. If price is within 20 pips of proximal value at time of major impact report, then Confirmation entry.
Trade management:
**When price hits 1:1 or T1, consider moving stop to entry in case of pullback.
**Disclaimer**:
The trading strategies, ideas, and information shared are for educational and informational purposes only. They do not constitute financial advice or a recommendation to buy or sell any securities, currencies, or financial instruments. You should do your own research or consult with a licensed financial advisor before making any trading decisions. The author assumes no responsibility for any losses incurred from following these trading ideas.
The fightback at support to continue higher is set-up nicelyAfter a selloff earlier in the day, the stock fought back and finished close to where it closed recently. Still, oversold levels remain, and with targets, it could be a swing to fill the gap at 280. Looking long term, it will be at the end of the year.
HUM is a BUY BUY BUY++++14 rsi on daily after the bounce from $208. We are WAY oversold here first target is $264.67 then $276.74 we are at major resistance on previous days high $245.79 then fell hard here. I bought calls this morning expiring today; will be worthless I will repurchase on Monday, this is a fantastic opportunity! but a low volume stock
Hum value swingI like to categorize my swing trades into sections. For longer term trades I like to buy 6 month or LEAP calls. In this case I believe Hum has fallen below intrinsic value fairly decently. I look to fill the gap at 278$ for my first target. The company is doing fine, revenues continue to grow, margins remain low but this is health insurance. I expect a full recovery of the entire massive candle around 350$ within the next 6-8 months.
My plan:
260$ Calls 6 months out
300$ Calls 18 months out
PT1= dashed green the GAP on the daily
PT2= 358$ hitting that second fib
HUM at the bottom?After a strong move to the downside, I think there is a good R:R on this trade for a bounce towards previous support to retest it as resistance. Worth the shot
Touch in the 250s entry or candle reversalIndicators are oversold, with earnings not too far this month. A few analysts have kept buying, maintaining, and holding ratings. No catalyst setting in, the medicare news scared a few, but don't think it results in much more of a more significant decline. The white box is a primary driver, which we should see picking up by another 20% minimally
HUM eyes on $275 for major support: time to start buying?Humana has been dumping for a while now.
Just dropped hard into a major support zone.
Scary entry here, but tight stop loss is possible.
There are many layers of resistance above.
So there will be many battles on the way up.
Maybe scalp or sell+buy pieces to build position.
I know nothing about this company or insurance.
But it pays good dividends and it is an insurance!
Long-term dollar-averaging entry could start here.
$ 274.86 - 280.07 is the major support for entry
$ 326.52 - 327.87 is the first major resistance.
$ 250.50 - 251.76 is next major support below.
===========================================
.
Bottom in for Humana? If so, that's a nice dip! Humana Inc. (HUM) recently experienced a significant drop of about 40%, landing on a 10-year support line. Is this the end of the decline for Humana? If so, this could present a very good buying opportunity.
- The RCI 3 line indicator shows a triple bottom.
- The RSI was oversold, reaching around 18, and has crossed above the moving average.
- The chart displays a rare buying signal, last seen in May 2019.
If the price recovers, a profit of 50% is possible. What do you think?
ClosE: HUM, STOP Reached, Loss -2%(or -8%) for 41dNYSE:HUM
ClosE: HUM, STOP Reached, Loss -2%(or -8%) for 41d
HUM Slide 14.67% Amidst Increase in Medicare Advantage PlansHumana's ( NYSE:HUM ) stock has experienced a significant decline of almost 15% in early trading on Tuesday, following the Centers for Medicare & Medicaid Services (CMS) announcement of a 3.7% increase in federal payments to Medicare Advantage plans. This increase matches the percentage increase proposed in January, leading to disappointment among investors and concerns regarding health insurers' profit margins, given the rising costs of medical care. The CMS has projected that the federal government will contribute between $500 billion and $600 billion in Medicare Advantage payments to private health plans in 2025, to maintain the stability of the program and ensure that payments are up-to-date and accurate.
Humana's CFO, Susan Diamond, had previously informed investors that the health insurer would fall short of its upper earnings-per-share growth target without a more significant increase in payments. The payment revision, which excludes the estimated growth in patient risk scores, represents a 0.16% decline, leading to disappointment among investors and health insurers who had lobbied for a higher increase. Research from JPMorgan cited by Bloomberg revealed that there has only been one instance in the past decade where Medical Advantage plan final rates have not increased from the government's initial rate proposals.
Other health insurers, including CVS Health, UnitedHealth Group, and Centene, have also experienced declines following the news, losing 5.9%, 4.5%, and 2.3%, respectively, in after-hours trading. However, Humana has been hit the hardest, with the stock falling 14.65% to $299.70 in early morning trading on Tuesday, putting it at levels not seen since the early days of the pandemic in March 2020.
Technical Outlook
With the Relative Strength Index (RSI) at 20 a break below the ceiling of the falling wedge is imminent thereby forming a new support at that level and spike after any major fundamentals. Allowing buyers to stack at that level.
Investors should keep an eye on a key horizontal trendline that stretches back to the stock's April 2020 pandemic recovery, an area that may attract buying interest around $318, amid Tuesday's expected news-driven sell-off to a multi-year low.
HUMANA swing alertHumana has been trading into key long term support.
This stock has been under severe pressure and is starting to appear to be carving out a potential base.
it seems that 1 more flush in this name may prove to be a swing tradable entry on the long side.
The weekly Death cross formation is close to occurring. This is no doubt a bearish long term signal but often this proves to be a buyable short term trade.
Health care stocks are something to be adding for long term!This set up at the bottom of the channel is a golden position.
The final gap down with a bull flag following is something to watch. Waiting for this to either gap up or form more bullish divergence.
Target is the upper end of the channel, taking profits at 20%-30%.
